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ABSTRACT
Cisplatin is a well-known anti-cancer drug that is effective, but also has some severe and
unwanted side effects. Analogs of cisplatin were reacted with the nonstandard amino acid
selenomethionine (SeMet), and the products were characterized by 1H and 195Pt NMR
spectroscopy and HPLC. In previous studies, SeMet was found to react faster than methionine
(Met) with a representative platinum complex (Pt(dien)Cl2), therefore SeMet is said to react faster
kinetically. Thus, while only a subset of proteins have selenium-containing amino acids,
platinum complexes could target them kinetically. Cisplatin analogs with two leaving groups
have also been studied. Pt(Me4en)(NO3)2 (Me4en = N,N,N’,N’-tetramethylethylenediamine)
reacts with SeMet to form a [Pt(Me4en)(SeMet-Se,N)]+ chelate regardless of the Pt:SeMet ratio.
Pt(en)(NO3)2 (en = ethylenediammine) reacts to form three possible products, with the
distribution dependent on the Pt:SeMet ratio and time.
INDEX WORDS: Cisplatin, Selenomethionine, Platinum(II) compounds, Hard-soft acid-base
theory, Trans effect, Nuclear magnetic resonance
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INTRODUCTION
It was estimated by the American Cancer Society that approximately 10,701,000 people
had a form of cancer in 2005, and the number of new cases each year continues to increase1.
Odds are that a person will know one person, if not more, with cancer during their lifetime. And
every person affected both directly and indirectly hopes that a cure will be found in time to help
them. There are many promising treatments currently in use but still researchers are working to
find more effective and less toxic treatments for a cancer cure. One such area of research is that
involving the use of platinum(II) compounds for cancer treatments. In fact, Tour de France
winner Lance Armstrong’s cancer was successfully treated using such a compound2. Like many
other developments in science, the discovery of cisplatin and its anti-cancer ability was an
accidental event that occurred during another experiment involving bacteria. Since its discovery,
many variations in the composition of the platinum(II) compounds have been developed and
researched to improve its anti-cancer activity. The research in this project looked at two such
compounds that are analogous to the structure of cisplatin.
The potential of cisplatin as an anticancer agent was stumbled upon around 1964.
Barnett Rosenberg was exploring the effects of an electric field on bacterial growth. The
experiment consisted of platinum electrodes in an aerobic solution of Escherichia coli with
ammonium chloride.3 Rosenberg was not looking for anticancer activity; he simply wanted to
know what would happen to the bacteria in an electric field. The results of the experiment
presented evidence that the cells were not participating in normal cellular division, but they did
appear to be grow into long filaments 300 times the normal length. It was soon determined that
the effects on the cells were not originating from the electrode alone, but an eletrolysis product in
the solution, cis-[Pt(NH3)2Cl2].4 This platinum compound was capable of compromising cell
division without cell death, which made it a candidate for preventing tumor growth with minimal
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damage done to cells of the host. Clinical trials were approved and began in the early 1970’s, and
cisplatin was FDA approved in 1979.
The chemistry of the platinum compound is important in that it results in specific
behaviors that can be utilized when it is combined with other compounds. Platinum(II), the form
in cisplatin, is an d8 transition metal with square planar geometry at the platinum atom. The
Pt(NH3)2Cl2 compound under normal biological conditions has two ammine ligands and two
chlorine ligands. Two arrangements are possible, a cis (Figure 1) and trans isomer. However, it
was shown in several studies that only the cis isomer is effective as an anticancer drug. Many
theories have been put forth as to why the trans isomer is not as effective, but no definite answer
or combination of reasons has been verified through experimentation. Platinum is described as a
“soft” acid. This results in platinum having a greater affinity for sulfur and nitrogen ligands.
This affinity greatly determines the main biological targets for platinum(II) compounds, such as
the sulfur of cysteine or methionine and nitrogen of guanine or adenine. The cysteine and
methionine represent the protein adduct of binding, while the guanine and adenine represent the
DNA adduct. Cisplatin and similar compounds possess a high specificity when binding so
reactions tend to progress slowly.
Cisplatin takes a specific path in the body and further within the cells due to its geometry
and cis conformation. Cisplatin is distributed intravenously where it remains neutral in the high
chloride (Cl-) concentration environment. The neutrality of the platinum compound allows it to
pass through the cell membrane into the cytosol of the cell, which contains a lower Clconcentration. The lower Cl- concentration causes the chlorides to be displaced by water
molecules. This substitution charges the overall compound preventing it from easily leaving the
cell. This new cisplatin-water compound can react with DNA adducts, protein adducts, or other
adducts in the cell. Reactions with protein adducts are thought to lead to detoxification, toxicity,
or transfer to DNA. Reactions with DNA adducts lead to either cell repair or cell death.
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Cisplatin’s effectiveness in the body in preventing tumor growth comes by distorting the
DNA within the cell. The main site of reaction with DNA is at the N7 atom of guanine, and the
major adduct that forms is a 1,2-intrastrand cross-link between adjacent guanines. The cisplatinDNA cross-link formation distorts the DNA structurally preventing it from replicating. The
distortion of the DNA is the main mechanism in its antitumor activity by preventing cancer cells
from replicating into new tumor cells. The trans isomer is not able to form the 1,2-intrastrand
cross-link, but leads to a different distortion, which is one of the suspected reasons that this
isomer is less effective at anticancer activity. This binding of cisplatin to DNA for distortion is
controlled kinetically and leads to cytotoxicity.3 Cisplatin is known to be toxic, carcinogenic,
teratogenic, and mutagenic, as well as to have interactions with several other kinds of substances.
Side effects of the drug during treatments can include renal toxicity, nephrotoxicity,
hypomagnesaemia, nausea, vomiting, diarrhea, ototoxicity, neurotoxicity, hematological effects,
sensitivity reactions, cardiovascular effects, ocular effects, and hepatic effects.5 It is apparent
that there is targeted cell death throughout the entire body and not just where cancer or a specific
tumor is present. Due to its extreme side effects, efforts are being made to alter the structure or
functionality of the platinum compound to reduce the amount of damage done to non-cancerous
cells in the body.
Methionine is an amino acid that contains a side chain with a thioether group6. As stated
earlier, Sherman and Lippard3 noted that the type of platinum(II) form in cisplatin has a high
affinity for sulfur, which makes methionine a prime target for reaction. Although, the platinum
would have a high affinity for sulfur, it is also capable of coordinating to a nitrogen or oxygen in
the compound. As mentioned earlier, platinum(II) is a soft acid and its reactivity can be related
according to the hard-soft acid-base theory. Assignment of a hard or soft characteristic is relative
to one element being compared to another, such as one atom being harder or softer when
compared to another atom. This theory can be applied to two atoms of interest in reaction to
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cisplatin: sulfur and selenium. Elements are considered softer if they have a larger radius, lower
electronegativity, and higher polarizability, which can represent movement down a group on the
periodic table among nonmetals. Selenium is one below sulfur in the Group VI elements. The
theory states that soft acids will prefer to react with soft bases, and hard acids will prefer to react
with hard bases. Since selenium is a softer element that sulfur, it is likely that it will react with
the soft platinum(II).7
Selenomethionine is a natural amino acid that has the same structure as methionine with a
selenium atom substituted for the sulfur atom6. Since selenium is considered to be softer than
sulfur it can be predicted that cisplatin and similar compounds would react with selenomethionine
than methionine. Researcher Steve Chmley has previously done experiments using an analog of
cisplatin ([Pt(dien)Cl]Cl) and reacting it with both methionine and selenomethionine. The results
that he gathered suggested that the reaction between [Pt(dien)Cl]Cl and selenomethionine was
kinetically favored over its reaction with methionine. The experiments also showed that over
time an equilibrium between the product of [Pt(dien)Cl]Cl with methionine and the product with
selenomethionine was established.
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Previous experiments have shown that cisplatin is capable of binding to the DNA adduct
in the cell and distorting the DNA to prevent replication. The platinum(II) form that makes up
cisplatin is a soft metal that has been shown to react faster with softer selenomethionine, but
comes to an equilibrium with methionine and selenomethionine. This project was about reacting
selenomethionine with two analogs of cisplatin: Pt(Me4en)(NO3)2 and Pt(en)(NO3)2. In previous
experiments with a Pt(Me4en)2+ compound, reactions with Met and N-AcMet have resulted in the
formation of one product. It is thought to be due to the steric hindrance of the platinum
compound’s structure (as shown in Figure 2). Reaction of Met and N-AcMet with a Pt(en)2+
compound is able to form multiple products due to a lack of steric hindrance and multiple
substitution positions available.

Two main techniques were used in the collection of data about the structures and
properties of the compounds and their products: Nuclear Magnetic Resonance Spectroscopy and
High-performance liquid chromatography. Nuclear Magnetic Resonance (NMR) is a
phenomenon in which the nuclei of particular atoms are immersed in a static magnetic field and
exposed to a second oscillating magnetic field. Spectroscopy is the phenomenon of the
interaction of matter with electromagnetic radiation. NMR spectroscopy uses the NMR
phenomenon to study the chemical, physical, and biological properties of matter. Many atomic
nuclei, such as hydrogen (1H) and platinum (195Pt), can be imagined as spinning around an axis,
said to be a nuclear spin. The charge of the molecule causes its nuclear spin to create a tiny
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magnetic field, which can then be manipulated by a larger magnetic field (or external magnetic
field).
In a simple case, when exposed to the external magnetic field, the nuclear spin can have
one of two orientations: aligned (! spin state) or against (" spin state). The aligned orientation is
energetically favorable, while the against is higher in energy. The right frequency produces
resonance when irradiation bridges the difference in energy between the two states by “flipping”
from one state to another. Afterward, it returns to its original state, and continues a cycle of
constant excitation and relaxation of the nuclei. The difference in the energy between the spin
states is directly related to the external field strength, which is directly proportional to the
absorption frequency. The energy of this absorption is referred to as the chemical shift. The
chemical shift of nuclei depends on the electron density surrounding it. Therefore, the chemical
shifts of nuclei can be used to determine the molecular structure of a species by the variations in
the electron densities around them.8
Another technique being used is high-performance liquid chromatography. Highperformance liquid chromatography (HPLC) is an enhanced version of column chromatography
used to identify, separate, and quantify compounds. HPLC makes use of a column that contains a
“packing material” called the stationary phase, a pumping system that pushes the mobile phase
through the column, and a detector. The stationary phase is part of the column and is what the
solutes in the mobile phase travel through and with which they interact. The mobile phase is the
part containing the solutes that interact with the stationary phase through the column. This kind
of technique takes advantage of a high affinity of proteins for specific chemical groups. This
project used cation exchange chromatography that is based on the separation of polar molecules
and ions due to the charge properties of the species. In cation exchange chromatography,
positively charged molecules are attracted to the negatively charged stationary phase.9
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These techniques were used in the project to characterize platinum (II) compounds
containing two leaving groups. The techniques were used to determine key reaction
characteristics in the two analogs of cisplatin being investigated in the project, and structural
characteristics of the product(s) formed after reaction with selenomethionine.
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MATERIALS AND METHODS
Synthesis of Pt compounds. Pt(en)Cl2 and Pt(Me4en)Cl2 were synthesized based on a
modification10 of a previous method of Romeo et al11. The chloride compounds were converted
to nitrate (NO-3) by addition of two equivalents of AgNO3, stirring in dark for 24 hours, filtering,
and drying.
Reaction of Pt compounds with L-SeMet. One or two molar equivalents of L-SeMet
were reacted with Pt(Me4en)(NO3)2 and the pH was adjusted to ~5.0. Pt(en)(NO3)2 was reacted
with L-SeMet and L-Met in 1:1, 2:1, or 1:3 Pt:ligand ratios and adjusted to a pH of ~5.0.
NMR Spectroscopy. Both 1H and 195Pt NMR spectra were attained on a JOEL Eclipse
500 MHz NMR instrument. The 1H NMR spectra obtained were adjusted for temperature and
referenced using the residual HOD signal relative to TSP.

195

Pt NMR spectra were referenced

relative to K2PtCl6 (0 ppm).
HPLC (High-performance liquid chromatography). The project used cation exchange
chromatography column to separate the three products of the reaction of Pt(en)(NO3)2 with LSeMet. The sample was eluded with 20 mM phosphate, pH 6 (Buffer A) and, 20 mM phosphate,
pH 6.0 and 0.5 M NaCl (Buffer B). Time zero minutes was a flow of 100% Buffer A, at 20
minutes there was 50:50 mixture of Buffer A and B, and after 25 minutes it returned to 100% of
Buffer A. The flow rate through the column was regulated at 0.5 milliliters/minute. The sample
was not collected after separation.

!

+!

!

!
RESULTS
Reaction of Pt(Me4en)(NO3)2 with SeMet. The addition of one equivalent of SeMet to
[Pt(Me4en)(H2O)2]2+ showed new resonances with singlets at 2.49 and 2.51 ppm in the 1H NMR
spectrum. Previous reaction between [Pt(Me4en)(H2O)2]2+ and Met led to similar sets of
resonances12; the product was assigned to [Pt(Me4en)(Met-S,N)]+, and the two singlets are due to
slow chirality exchange at the S atom. Thus, the signals in the SeMet spectrum are assigned to a
single product, [Pt(Me4en)(SeMet-Se,N)]+, with differing chirality around the selenium atom.
There was a 1:1 ratio between Pt(Me4en)2+ and SeMet based on integration of the NMR signals.
Support for the assignment came from the 195Pt NMR spectrum, which showed two peaks at
-3190 and -3260 ppm. These results were similar to the values of -3160 and -3230 ppm for Met
and Pt(Me4en)2+, and to the product of [Pt(dien)(SeMet-Se)]+.!

!
Reaction of Pt(en)(NO3)2 with SeMet. The addition of SeMet to Pt(en)(NO3)2 showed
multiple peaks ranging from 2.4 to 2.5 ppm leading to three different products: monochelate, bis,
and bischelate. The monochelate product showed resonances with a set of two singlets at 2.4
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ppm in the NMR spectrum. The resonances were dominant in reactions containing low SeMet:Pt
ratios. Reaction of Pt(Me4en)(NO3)2 with SeMet led to similar resonance signals. The bis
product showed resonances with two singlets at 2.5 ppm in the NMR spectrum. These
resonances were dominant in reactions containing higher SeMet:Pt ratios. The en signal at 2.7
ppm is a singlet relating to its C2 symmetry. The bischelate product showed resonances with one
singlet and two doublets between 2.4-2.5 ppm in the NMR spectrum. There is also the presence
of free en indicated by a signal at 3.35 ppm. This product is formed from the bis product with the
presence of excess SeMet. The doublet at 2.5 ppm related to the bis product disappears as the
bischelate singlet and doublets between 2.4-2.5 ppm appears. This product does not form from
the monochelate product even in the presence of excess SeMet.
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This reaction was also analyzed with high-performance liquid chromatography (HPLC).
The three products from the reaction of Pt(en)(NO3)2 with SeMet were separated by their
different charges using a Hitachi Elite LaChrom: Pump L-2130 and UV Detector L-2400 cation
exchange column. The bischelate product is neutral and was the fastest product to travel through
the column indicated by a peak at 2-3 minutes. The monochelate product has a charge of +1
associated with it and was indicated by a peak at 5 minutes. The bis product has a charge of +2
associated with it and was indicated by a peak at 15 minutes to move through the column. The
buffers used to move the sample through the column were 20 mM phosphate, pH 6 and 0.5 M
NaCl.
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DISCUSSION!
It has been shown in previous experiments that the type of platinum(II) form making up
the structure of cisplatin reacts faster kinetically with SeMet than Met. Expanding on this
suggestion, it was the purpose of this project to take two analogs of the cisplatin compound and
react them with SeMet to characterize their products. Both the analogs have two leaving groups
of either chlorides or nitrates that relate to the structure of cisplatin. The two leaving groups are
important for creating an overall chemistry to easily move the compound through the cell
membrane and then be replaced to prevent it leaving the cell. The differences in the analogs from
cisplatin were meant to look at the effects that bulk can play in binding with SeMet.
The results of the project in certain areas can be used to formulate a prediction of the
SeMet adduct in these reactions. It is possible to predict the SeMet adduct characterization with
the behavior of the reaction of Pt(Me4en) with SeMet. The product [Pt(Me4en)(SeMet)-Se,N]+
with its two chiralites were represented by specific peaks in both the 1H and 195Pt NMR spectra,
which were similar to peaks seen previously with the reaction of Pt(Me4en) with Nactylmethionine (N-AcMet) and Met. This allows for certain similarities to be drawn regarding
the structure and other characteristics of the product.
One of the main focuses of the results with the project has been on a phenomenon called
the trans effect. The trans effect is related to platinum(II) compounds and suggests that ligands
trans to a chloride, sulfur, or selenium atom are more easily displaced than when trans to an
ammonia group. This effect is known to be a kinetic effect and not thermodynamic, meaning that
it requires a compound effective at substituting for the reaction to work properly. It prefers to
interact with ligands or elements that are kinetically favored, as opposed to those that are
thermodynamically favored.7 There are several culminating factors that suggest this effect is
taking place in some of the reactions and not taking place in others.
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The reaction of SeMet with Pt(en) results in separate products dependent on the Pt:Se
ratio present. In a low Se:Pt ratio the monochelate product is prominent, while in a high ratio the
bis and bischelate product is more prominent. The low Se:Pt ratio favors the monochelate
product mainly due to there being less SeMet compounds to Pt compounds, making the
probability of double substitution with SeMet unlikely. Although the substitution with SeMet is
faster than the formation of the chelate on the monochelate product, without a second substitution
(due to low concentration) the nitrogen of one of the amine groups will chelate and prevent
further substitution. The bischelate product formed from the reaction of Pt(en) with SeMet in a
high Se:Pt ratio only appears after the formation of the bis product. In 1H NMR spectra taken at
several intervals over a period of time, the signals for the bis product disappear and the bischelate
signals begin to form. There are no peaks indicating that the bischelate product is present at the
initial stage of the reaction. In a reaction with low Se:Pt ratio favoring the monochelate product,
there appears no formation of the bischelate product. This is due to the presence of the
monochelate labilizing only one of the Pt-N bonds, which directly affects the formation of the
bischelate product by breaking the chelate. Formation of a new chelate would be unfavoarable,
therefore there would be no formation of a bischelate product. Even adding excess of N-AcMet
after forming a monochelate product with N-AcMet, it took approximately three months at a pH
of ~2.0 before any change was observed.
The process of the trans effect with this compound is achieved by the chelated ligands
that are displaced when the sulfur or selenium ligand attaches trans to both nitrogen ligands. The
entire process uses the formation of two chelates to replace one. The first step in the process is to
replace an N,N chelate (two chelated amine groups) with an Se,N chelate. The first step is
assumed to be thermodynamically neutral. The second step is to displace the rest of the N,N
chelate to form a second Se,N chelate, which should be favorable. The free N,N chelate (free en)
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is then visible with its own signal. At no point was there indication that an intermediate form was
being observed in the NMR data.
Many studies have been done with cis/carbo-platin in which the amine groups are not
chelated. In those experiments that were performed, the results suggested that the non-chelated
amine groups were easier to displace than chelated amines. This is strongly influenced by the
chelate forming a more rigid structure to the central atom.13
Platinum (II) has a high affinity for sulfur, and it is possible that sulfur-containing
biomolecules other than DNA may have an important role in the metabolism and mechanism of
action or cisplatin. Higher affinity for selenium may cause it to have the same role as sulfur, and
it has been shown in in vivo studies to prevent cisplatin-induced drug resistance and toxicity.
However, it does not affect the cytotoxicity of cisplatin. Greater affinity for SeMet, along with
cisplatin’s high specificity, may lead to new methods of targeting and reactions within the cell.14
Although the specific mechanisms involved in the reaction of two cisplatin-like
compounds with selenomethionine are not fully understood, the trans effect plays a significant
role in one of them. The reactions produced four products that were identified and characterized
from NMR spectra and HPLC data and the significance of these products could be the focus of
future research. The anticancer properties of selenomethionine and its reduced cellular toxicity
make it a promising area for further cancer reaserch. The knowledge gained from the project
could provide insight into the specific mechanisms that occur in the reactions and if they will
have significance in reactions with other molecules.!
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